Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
Boca Raton, FL - On April 14, Marlan D. Walker, the Chief Executive Officer of TherapeuticsMD, Inc. (NASDAQ:TXMD), acquired 490 shares of the company’s common stock. The shares were purchased at a price of $0.9985 per share, amounting to a total transaction value of $489. The purchase comes as TXMD shares show strong momentum, with a 17% gain over the past week and nearly 20% year-to-date, according to InvestingPro data.
Following this transaction, Walker’s direct ownership in TherapeuticsMD stands at 73,639 shares. The purchase reflects a modest increase in his holdings in the pharmaceutical company, which specializes in women’s health products. The company maintains a healthy financial position with a current ratio of 2.37, indicating strong liquidity. Analysts tracked by InvestingPro expect positive earnings this year, with revenue growth forecast at 4.2%.
TherapeuticsMD, headquartered in Boca Raton, Florida, continues to focus on its strategic initiatives in the life sciences sector. Trading at 0.44 times book value, the stock currently appears undervalued based on InvestingPro’s Fair Value analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.